A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

Konstantinos Tryfonidis, Gul Basaran, Jan Bogaerts, Marc Debled, Luc Dirix, Jean-Christophe Thery, Vivianne C. G. Tjan-Heijnen, Danielle Van Den Weyngaert, Tanja Cufer, Martine Piccart, David A. Cameron

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)144-154
Number of pages11
JournalEuropean Journal of Cancer
Volume53
DOIs
Publication statusPublished - Jan 2016

Keywords

  • Anastrozole
  • Gefitinib
  • Metastatic breast cancer
  • Endocrine resistance

Cite this